CSIMarket
 


Ascendis Pharma A  (ASND)
Other Ticker:  
 

Ascendis Pharma A's Working Capital Ratio

ASND's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the forth quarter 2022, Working Capital Ratio deteriorated to 1.86 a new company low.

Within Major Pharmaceutical Preparations industry 464 other companies have achieved higher Working Capital Ratio than Ascendis Pharma A in forth quarter 2022. While total ranking remained the same in the IV Quarter 2022 compared to the third quarter 2022 at no. 2870.

Explain Working Capital Ratio
How much in Current Assets ASND´s has?
What is the value of ASND´s Current Liabilities?


ASND Working Capital Ratio (Dec 31 2022)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Dec 31 2021)
IV. Quarter
Y / Y Current Liabilities Change 394.03 % 394.03 % 394.03 % 394.03 % 90.05 %
Y / Y Current Assets Change 14.59 % 14.59 % 14.59 % 14.59 % 8.88 %
Working Capital Ratio MRQ 1.86 1.86 1.86 1.86 8.03
ASND's Total Ranking # 2870 # 2870 # 2870 # 2701 # 282
Seq. Current Liabilities Change 0 % 0 % 0 % 394.03 % 0 %
Seq. Current Assets Change 0 % 0 % 0 % 14.59 % 0 %



Working Capital Ratio forth quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 465
Healthcare Sector # 891
Overall Market # 2870


Working Capital Ratio Statistics
High Average Low
14.02 8.58 1.86
(Dec 31 2020)   (Dec 31 2022)




Financial Statements
Ascendis Pharma A's Current Liabilities $ 555 Millions Visit ASND's Balance sheet
Ascendis Pharma A's Current Assets $ 1,034 Millions Visit ASND's Balance sheet
Source of ASND's Sales Visit ASND's Sales by Geography


Cumulative Ascendis Pharma A's Working Capital Ratio

ASND's Working Capital Ratio for the trailling 12 Months

ASND Working Capital Ratio

(Dec 31 2022)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Dec 31 2021)
IV. Quarter
Y / Y Current Liabilities TTM Growth 394.03 % 394.03 % 394.03 % 394.03 % 90.05 %
Y / Y Current Assets TTM Growth 14.59 % 14.59 % 14.59 % 14.59 % 8.88 %
Working Capital Ratio TTM 1.86 2.25 2.9 4.19 8.03
Total Ranking TTM # 4954 # 4795 # 4788 # 4290 # 4858
Seq. Current Liabilities TTM Growth 0 % 0 % 0 % 394.03 % 0 %
Seq. Current Assets TTM Growth 0 % 0 % 0 % 14.59 % 0 %


On the trailing twelve months basis Due to unchange in Current Liabilities in the IV Quarter 2022 to $555.28 millions, cumulative Working Capital Ratio decreased to 1.86 below the Ascendis Pharma A average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 583 other companies have achieved higher Working Capital Ratio than Ascendis Pharma A. While Working Capital Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2022 from 4795 to 4954.

Explain Working Capital Ratio
How much in Current Assets ASND´s has?
What is the value of ASND´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 584
Healthcare Sector # 1211
Within the Market # 4954


trailing twelve months Working Capital Ratio Statistics
High Average Low
14.02 10.29 1.86
(Dec 31 2020)   (Dec 31 2022)




Companies with similar Working Capital Ratio in the quarter ending Dec 31 2022, within Major Pharmaceutical Preparations Industry Working Capital RatioDec 31 2022 MRQ Current AssetsDec 31 2022 MRQ Current Liabilities
Evelo Biosciences Inc   5.09 $ 51.573  Millions$ 10.136  Millions
Salarius Pharmaceuticals inc   5.08 $ 14.520  Millions$ 2.858  Millions
Harmony Biosciences Holdings inc   5.07 $ 400.285  Millions$ 78.884  Millions
G1 Therapeutics Inc   5.04 $ 179.500  Millions$ 35.588  Millions
I mab  5.00 $ 525.789  Millions$ 105.191  Millions
Elite Pharmaceuticals Inc   5.00 $ 33.257  Millions$ 6.654  Millions
Revance Therapeutics Inc   4.95 $ 374.727  Millions$ 75.682  Millions
Lipella Pharmaceuticals Inc   4.92 $ 5.799  Millions$ 1.178  Millions
Unity Biotechnology Inc   4.92 $ 96.535  Millions$ 19.620  Millions
Enveric Biosciences Inc   4.92 $ 18.432  Millions$ 3.747  Millions
Schrodinger Inc   4.91 $ 533.989  Millions$ 108.799  Millions
Biolinerx Ltd   4.87 $ 52.001  Millions$ 10.679  Millions
Hoth Therapeutics Inc   4.85 $ 6.726  Millions$ 1.388  Millions
Vertex Pharmaceuticals Inc  4.83 $ 13,234.800  Millions$ 2,742.100  Millions
Sarepta Therapeutics Inc   4.82 $ 2,557.861  Millions$ 530.360  Millions
Decibel Therapeutics Inc   4.81 $ 108.030  Millions$ 22.442  Millions
Corbus Pharmaceuticals Holdings Inc   4.76 $ 60.181  Millions$ 12.640  Millions
Galmed Pharmaceuticals Ltd   4.76 $ 14.724  Millions$ 3.094  Millions
Deciphera Pharmaceuticals Inc   4.72 $ 392.958  Millions$ 83.234  Millions
Arrowhead Pharmaceuticals Inc   4.71 $ 574.999  Millions$ 122.009  Millions
Purple Biotech Ltd   4.71 $ 33.256  Millions$ 7.058  Millions
Trevena inc   4.70 $ 41.008  Millions$ 8.732  Millions
Biomarin Pharmaceutical Inc  4.67 $ 2,751.457  Millions$ 588.884  Millions
Procyon Corporation  4.66 $ 2.280  Millions$ 0.489  Millions
Pharming Group N v   4.65 $ 277.500  Millions$ 59.698  Millions
Y mabs Therapeutics inc   4.61 $ 130.447  Millions$ 28.284  Millions
Arbutus Biopharma Corp  4.60 $ 151.139  Millions$ 32.857  Millions
Macrogenics Inc   4.57 $ 222.180  Millions$ 48.611  Millions
Scynexis Inc   4.56 $ 79.061  Millions$ 17.336  Millions
Acurx Pharmaceuticals inc   4.55 $ 9.377  Millions$ 2.062  Millions

Date modified: 2023-03-23T21:49:59+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com